Flexion Therapeutics (FLXN) Appoints Utpal Koppikar to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Take-Two stock drops as GTA 6 leaks continue
- GameStop posts higher income despite revenue drop in Q2 2026
- At least eight die, 18 missing after ferry capsizes off North Cyprus
- Goldman Sachs raises humanoid robot forecast, sees auto role
- Manhunt underway after woman killed, several injured at Swiss rave shooting
Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors
July 12, 2021 4:30 PM EDTBURLINGTON, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq: FLXN) today announced the appointment of Utpal Koppikar, Chief Financial Officer of Atara Biotherapeutics, to its Board of Directors. Mr. Koppikar will serve as the chair of Flexions audit committee.
"I am thrilled to welcome Utpal to Flexions Board, as his extensive financial experience leading biotechnology companies makes him an outstanding addition to our Board of Directors, said Michael Clayman, MD, President and Chief Executive Officer of Flexion Therapeutics. In addition to Utpals anticipated contributions guiding our corporate strategy, I... More
